definiens: shall mean the period beginning on the Effective Date and continuing either if Merck exercises its for continued Exclusive Efforts in accordance with Section 2.1, or ( b ) if Exclusive Efforts in accordance with Section 2.10, until the ... ... . . ' .... ' . At any time during the ~t!g~ . Period that Metabasis, in its sole discretion, determines that a HCV antiviral compound 1,,1WWU incorporating HepDirect under the Metabasis Internal ) is . ...., . 1111 . ., . · . ~ ., Metabasis shall so notify Merck in writing and provide Merck with all available data on such Metabasis Internal Program Compound, which shall include, without limitation, a data package consisting of the items described in the Parties letter dated concurrently herewith but shall initially exclude [ It . All information disclosed to Merck PWli)UCUlL 8.2 ( including, without limitation, shall be deemed Confidential Information of Metabasis . Within of receipt by Merck of such notice and all such information, Merck shall notify Metabasis if Merck is interested in conducting further safety studies on such Metabasis Internal If Merck so notifies Metabasis of its . Metabasis shall disclose be responsible for Further, if Merck so notifies Metabasis of its intent, Metabasis shall supply of such Metabasis Internal Program Compound ( J ) and, at Merck 's expense, Merck may itself conduct, or at Merck 's option, reimburse Metabasis to conduct, safety studies on such Metabasis Internal Program Compound during the _ -'-J period following receipt by Merck of such quantities of such Metabasis Internal Program Compound or such longer period as the Parties may agree ( the ), provided that Metabasis shall have no obligation to consent to any extension of the Safety Review Period beyond such initial _ . In no event will Merck attempt to reverse engineer, deconstruct or in any way determine the structure or composition of any Metabasis Internal Program Compound disclosed or provided hereunder . Merck shall disclose all results of and data from safety studies of any Metabasis Internal Program Compound conducted by or on behalf of Merck ( except that Merck shall not be obligated to disclose any Merck or Third Party proprietary methods or processes utilized in such studies ), and all of such results and data shall be the sole and exclusive property, and the Confidential Information, of Metabasis ; provided, however, all such results and data shall be transferred to Metabasis on an basis without any representation or warrant of any kind, and Metabasis shall be fully liable, and Merck shall have no liability, for any use of such 31 CONFIDENTIAL TREATMENT REQUEST(ED ) results and data by Metabasis for any and all purposes . Within [ 1 after ( i ) if Merck requested fwther safety studies, the later of the expiration of the Safety Review Period or if Metabasis is conducting such safety studies, the date of receipt by Merck of all data generated as a result of such Metabasis safety studies, or ( ii ) if Merck does not request further safety studies, the date on which Merck notified Metabasis of such fact in accordance with this Section 8.2, Merck may exercise its option for an exclusive development and commercialization license for such Metabasis Internal Program Compound which shall include, without limitation, the following terms : Type of Payment Option Fee ..................................................................